Bicara Therapeutics Inc.
BCAX
$9.32
-$0.11-1.17%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -75.82% | -19.88% | -18.29% | -18.15% | -0.55% |
| Total Depreciation and Amortization | 26.67% | 0.00% | 15.38% | 0.00% | -7.14% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 23.55% | 38.40% | 81.26% | -4.46% | -16.18% |
| Change in Net Operating Assets | 142.78% | -545.93% | -1,226.43% | 95.76% | -212.23% |
| Cash from Operations | 6.41% | -74.36% | -25.29% | 5.76% | -81.52% |
| Capital Expenditure | -- | -400.00% | 30.43% | -187.50% | 99.08% |
| Sale of Property, Plant, and Equipment | -- | -- | -100.00% | -50.00% | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -400.00% | -141.03% | -66.38% | 113.30% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | 45,372.26% | 435.40% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 300.00% | -- | -- |
| Cash from Financing | 147.18% | -100.29% | 76,624.45% | 217.88% | -99.93% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 10.95% | -109.80% | 2,484.07% | 7.64% | -107.73% |